Iron chelates in the anticancer therapy

Abstract Iron plays a significant role in the metabolism of cancer cells. In comparison with normal cells, neoplastic ones exhibit enhanced vulnerability to iron. Ferric ions target tumor via ferroptotic death pathway—a process involving iron-mediated lipid oxidation. ion occurs complex forms physiological conditions. Apart from iron, ligands are other factors affect biological activity iron complexes. recent decades chelates targeting growth was extensively examined. The ligand may possess standalone restrict cancer’s growth. However, wrong choice might lead cell’s vitro studies. paper aims review compounds anticancer therapy both experimental and clinical applications. properties rely on stability constant composition. When is high, drug unique. when remains low, components—ferric ligands, act separately we show how difference implies action ferric cell. complexation strategy an interesting attempt transport Fe 2+/3+ throughout cell membrane release it pH microenvironment changes. Last part summarizes results trials studies novel such as: PRLX 93,936, Ferumoxytol, Talactoferrin, DPC, Triapine, VLX600, Tachypyridine, Ciclopiroxamine, Thiosemicarbazone, Deferoxamine Deferasirox.